Research consistently shows that when body weight decreases, the body loses both fat mass and lean muscle mass, not fat alone. Muscle plays an essential role in strength, balance, mobility, and metabolic function
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
Freeze-thaw rule If long-term storage is needed, freeze single-use aliquots rather than the same vial over and over
Lilly's Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results
Who should not take retatrutide
Call 999 or go to A&E immediately if you experience signs of a serious allergic reaction (widespread rash, difficulty breathing, facial or throat swelling)